PTJ
GLUE icon

Paul Tudor Jones’s Monte Rosa Therapeutics GLUE Stock Holding History

Paul Tudor Jones’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$227K – 2584
2021
Q2 		$227K Buy
+10,000
New +$204K ﹤0.01% 1445

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Paul Tudor Jones's GLUE Position: Q3 2021 in Review

Paul Tudor Jones sold out of Monte Rosa Therapeutics (GLUE) in Q3 2021, closing a stake of 10,000 shares — an estimated $227K sold.

Paul Tudor Jones first reported a position in GLUE in Q2 2021 and held it in 1 quarter. The position peaked at $227K in Q2 2021. 56 funds tracked by Wall St. Rank hold GLUE as of Q3 2021.

  • Paul Tudor Jones reported no remaining Monte Rosa Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Paul Tudor Jones sold 10,000 Monte Rosa Therapeutics shares in Q3 2021, an estimated $227K.
  • Paul Tudor Jones first reported a position in Monte Rosa Therapeutics in Q2 2021 and held it in 1 quarter.
  • Paul Tudor Jones's Monte Rosa Therapeutics position peaked at $227K in Q2 2021.
  • 56 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2021.

Based on Tudor Investment Corp's 13F filing for Q3 2021, filed 15 Nov 2021.